Loading...
Genmab achieves milestone with Amgen license agreement by delivering an antibody
18-Sep-2003
Advertisement
Copenhagen, Denmark - Genmab A/S announced today that it has achieved a milestone in its license agreement with Amgen by delivering an antibody that targets the IL15 receptor.
Under the terms of the agreement, Genmab will receive a milestone payment of USD 500,000.
"We are pleased to reach a milestone in our agreement with Amgen," said Lisa N. Drakeman, Ph. D. Chief Executive Officer of Genmab.